Background: Plaque psoriasis, which is a chronic immune-mediated inflammatory skin condition, significantly reduces patients' quality of life. The cytokine interleukin-23 (IL-23) is a pivotal factor in the development of psoriasis, and icotrokinra is a new oral IL-23 receptor antagonist that has shown potential effectiveness in clinical trials. The main goal of this systematic review and meta-analysis was to assess the effectiveness and safety of icotrokinra in adults and adolescents with moderate-to-severe plaque-type psoriasis. Methods: A comprehensive literature search in PubMed, ScienceDirect, and the Cochrane Library, conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards, identified randomized controlled trials that evaluated daily oral icotrokinra 200 mg versus placebo. The primary outcomes were Psoriasis Area and Severity Index (PASI) 90, Investigator's Global Assessment (IGA) 0/1, and adverse events (AEs) at 16 weeks. Risk ratios with 95% confidence intervals were summed up through a random-effects model. Results: A total of five randomized controlled trials involving 2,755 participants were included. Icotrokinra showed a significant increase in PASI 90, IGA 0/1, IGA 0, and Psoriasis Symptoms and Signs Diary 0 responses compared to placebo. The overall frequency of AEs was similar in both groups, but the rate of treatment discontinuation due to AEs was lower with icotrokinra. Conclusions: Icotrokinra is an effective and well-tolerated oral treatment for moderate-to-severe plaque psoriasis with considerable clinical and patient-reported benefits.
Icotrokinra (JNJ-2113) is a first-in-class targeted oral peptide that selectively binds to the interleukin-23 (IL-23) receptor and blocks IL-23 signaling. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) of Icotrokinra to assess its efficacy and safety versus control in moderate-to-severe plaque psoriasis. We performed a PRISMA-adherent systematic literature search across Scopus, PubMed, and Web of Science from their inception up to January 2026. Screening, data extraction, and risk of bias assessment were made by two independent authors. A meta-analysis was conducted in R with sensitivity and subgroup analyses. We included four studies comprising five RCTs. Oral icotrokinra significantly improved physician-assessed and psoriasis area and severity index (PASI) responses compared with control in RCTs. For Investigator’s Global Assessment (IGA) 0/1, benefit was evident by week 2 (risk ratios (RR) = 3.24%, 95% confidence interval (CI) 1.01–10.46) and remained consistent through week 16 (RR = 7.35%, 95% CI 5.67–9.54), with an overall pooled effect RR = 7.31 (95% CI 6.25–8.55). Complete clearance (IGA 0) emerged from week 8 (RR = 23.65%, 95% CI 6.74–82.95), overall RR = 12.44 (95% CI 6.88–22.51). PASI 75 overall RR = 6.74 (95% CI 5.75–7.91); PASI 90 RR = 14.38; PASI 100 RR = 11.17. PSSD symptom 0 at week 16: 256/1226 vs 9/551 (RR=9.62%, 95% CI 5.14–18.01). Icotrokinra offers rapid and clinically significant improvements in plaque psoriasis, particularly on IGA and PASI, and these responses continue to improve over time; by week 8, complete clearance became significantly more frequent with icotrokinra. Safety outcomes were comparable between icotrokinra and placebo, and there was no meaningful increase in serious adverse events.
plaque psoriasisIL-23 receptor antagonistPASI responseInvestigator's Global Assessment
The long-term comparative outcomes of on-pump and off-pump coronary artery bypass grafting (CABG) remain disputed. We performed a random-effects meta-analysis of 25 randomized controlled trials (18,729 patients) comparing on-pump versus off-pump CABG, searching MEDLINE/PubMed, Cochrane CENTRAL, Web of Science, ProQuest, ClinicalTrials.gov, Scopus, and grey literature through 7 June 2025. Outcomes (repeat revascularization, late myocardial infarction, stroke/TIA, late mortality, major adverse cardiovascular events [MACE], and composite endpoints) were pooled as hazard ratios (HR) with 95% confidence intervals (CI), expressed as on-pump versus off-pump. On-pump CABG significantly reduced late myocardial infarction (HR 0.58; p = 0.01). Off-pump CABG was associated with significantly lower MACE (HR 1.62; p = 0.003), with the greatest benefit at 5–10 years (HR 2.18; p < 0.00001) and persisting beyond 10 years (HR 1.89; p = 0.03), and with a lower composite-endpoint risk (HR 1.24; p = 0.04). No significant differences were found for late mortality, repeat revascularization, or stroke/TIA. Risk of bias was moderate to high, and the certainty of evidence was low to very low for most outcomes. On-pump CABG confers a long-term reduction in myocardial infarction, whereas off-pump CABG is associated with a lower MACE and composite cardiovascular event burden; neither technique differs for late mortality, repeat revascularization, or cerebrovascular events. Surgical strategy should be individualized, and further high-quality trials are warranted.
Background: Chemical peels are widely used for mild-to-moderate acne vulgaris, but comparative evidence is dispersed across small trials and multiple active formulations. This review synthesized the supplied randomized evidence and compared efficacy and tolerability across peel types using network meta-analysis. Methods: PubMed, the Cochrane Library, Scopus, and Web of Science were searched for randomized active-comparator trials of chemical peels for acne vulgaris up to June 2026. Random-effects network meta-analyses used standardized mean differences (SMDs) for continuous outcomes and risk ratios (RRs) for categorical and safety outcomes, each with 95% confidence intervals (CIs). Salicylic acid was the reference treatment, and treatments were ranked using surface under the cumulative ranking curve (SUCRA) values. Results: Twenty-three randomized trials with reported enrollment totaling 1,170 participants were included. Most continuous efficacy comparisons were not statistically significant. Relative to salicylic acid, Jessner's solution was associated with a smaller reduction in papule count (SMD 2.49, 95% CI 1.28 to 3.70) and a smaller reduction in Michaelsson acne score (SMD 1.78, 95% CI 0.41 to 3.16). Salicylic plus mandelic acid ranked highest for good improvement (SUCRA 91.9%), but its RR versus salicylic acid was imprecise (RR 1.96, 95% CI 0.75 to 5.13). Trichloroacetic acid was associated with more erythema than salicylic acid (RR 2.74, 95% CI 1.10 to 6.78). Heterogeneity was substantial for non-inflammatory lesion count, papule count, pustule count, and Michaelsson acne score. Treatment-label fragmentation and undocumented handling of split-face correlations limited confidence in rankings. Conclusion: Our analysis does not establish broad superiority of one chemical peel for acne vulgaris. Salicylic acid performed favorably against Jessner's solution for selected efficacy outcomes and had a lower erythema risk than trichloroacetic acid, but most estimates were imprecise and several networks were heterogeneous. Treatment choice should remain individualized, and the findings require confirmation in rigorously reported head-to-head trials with standardized outcomes.
chemical peelsacnesalicylic acidJessner's solution
AIM- The objective of the systematic review is to evaluate the incidence of postoperative pain after single-visit and multiple-visit root canal therapy. METHODS- Published research indexed in PubMed or Scopus or Cochrane or DOAJ or Web of Science evaluating the frequency percentage of postoperative aching after one and several root canal therapy appointments through randomized controlled trials or prospectively were included. RESULT- Most surveys utilized VAS (Visual Analogue Scale) to estimate the degree of pain among the participants. The majority of the studies (n-8) showed no difference between postoperative pain during single-sitting endodontic treatment or multiple-sitting endodontic treatment. On the contrary, several studies (n-6) also revealed that post-obturation pain in a single-appointment root canal therapy is less compared to multi-visit root canal therapy. The current research results give insight into the incidence of postoperative endodontic pain among the study participants undergoing root canal treatment through single or multiple visit appointments. CONCLUSION- The lack of consistency between studies is due to the different ways in which pain intensity is measured and differences in treatment methods, patient selection and treatment outcomes.
AIM: To evaluate the efficacy and outcomes of integrative technologies employed in nursing-led interventions for the management of diabetes. BACKGROUND: With the global rise in diabetes prevalence, there is growing interest in digital health solutions to improve disease self-management. Nurses are increasingly leveraging technologies, such as mobile applications, wearable devices, and telehealth platforms, to support individuals with diabetes. However, the effectiveness and implementation outcomes of such nursing-led digital interventions remain variably reported in the literature. METHODS: A systematic review was conducted following PRISMA 2020 guidelines. Comprehensive five database searches (PubMed, CINAHL, Scopus, Web of Science, and Embase) identified randomized controlled trials (RCTs) from 2013 to 2024. Studies were included if they involved nurse-led interventions incorporating digital technologies for diabetes management. Data were synthesized using narrative and thematic analysis. Risk of bias was assessed using the RoB 2 tool. RESULTS: Thirteen RCTs involving diverse technologies demonstrated improvements in glycemic control (HbA1c reduction), self-management behaviors, and quality of life. Interventions incorporating personalized coaching, regular follow-up, and patient-centered feedback were particularly effective. Most studies were rated as low risk of bias, though some showed concerns regarding reporting practices and intervention fidelity. CONCLUSION: Nursing-led digital health interventions can significantly enhance diabetes care outcomes. Their success is contingent upon sustained patient engagement, nurse training, and organizational support. Broader implementation requires addressing digital literacy and system-level integration challenges. IMPLICATIONS FOR PRACTICE: Nurse-led technologies should be embedded in care models to support scalable, personalized, and effective diabetes self-management across diverse settings. CLINICAL TRIAL NUMBER: Not applicable.
diabetes managementnurse-led interventiondigital health technologiesmobile health apps
Lipids in Health and Disease · مجلد 24 (1) · 109-109
BACKGROUND: Hypertriglyceridemia is an independent risk factor for cardiovascular diseases. In previous trials, apolipoprotein C-III (APOC3) inhibition through the antisense oligonucleotides volanesorsen, olezarsen, and plozasiran reduced triglyceride levels. However, the three medications' safety and efficacy have yet to be compared. METHODS: A network meta-analysis was performed to compare multiple doses of the three medications to each other through the placebo. Randomized controlled trials (RCTs) were retrieved by searching PubMed, EMBASE, Web of Science, SCOPUS, and Cochrane until November 22nd, 2024. The mean difference (MD) and 95% confidence interval (CI) were used for continuous outcomes. The risk ratio (RR) and 95% CI were used for dichotomous outcomes. RESULTS: Ten RCTs with a total of 1,129 patients were included. volanesorsen 300 mg once weekly showed the most significant percent reduction in triglyceride levels (MD = -91.0%, 95% CI: (-109.2%; -72.8%); P < 0.01). Only plozasiran once monthly, regardless of the dose, showed a non-significant percent reduction in triglycerides. This finding should be taken cautiously as the data were derived from a phase 1 trial with a small sample size. All the regimens significantly reduced APOC3 levels compared to placebo, with plozasiran 100 mg monthly and volanesorsen 300 mg once weekly showing the most significant reduction (MD range: -92.8% to -88.5%; P < 0.01). None of the treatments showed a statistically significant difference in overall adverse events rate compared to the placebo. CONCLUSION: APOC3 antisense oligonucleotide inhibitors effectively reduced triglyceride and APOC3 levels in hypertriglyceridemia with an acceptable safety profile. However, the results should be interpreted cautiously due to the small sample size. Further research is needed to confirm the beneficial effects of APOC3 inhibitors and show strong evidence of the impact of each regimen.
Background: Ankle injuries are some of the most common injuries among footballers and can prevent players from participating in sport. The Fédération Internationale de Football Association (FIFA) developed FIFA injury prevention programs to reduce overall football injuries, but their effectiveness on a particular joint, such as the ankle, was not assessed. Therefore, this project aims to investigate if these FIFA injury prevention programs are particularly effective in reducing ankle injuries. Method: A systematic review was conducted with the following criteria for study selection: Randomized controlled trials (RTCs) comparing the FIFA programs (FIFA 11 the old version and FIFA 11+) with the usual training for the teams. Other studies that included the number or percentage of ankle injuries as an outcome. Sample: Male and female footballers aged between 13 and 40 years old and without any restriction on particular skill levels. The Physiotherapy Evidence Database scale (PEDro) was used to assess the methodological quality of the included studies. Results: The search strategy identified five RCTs that used the FIFA programs. The included studies had a good-to-excellent methodological quality according to the PEDro scale (ranging from 5 to 7 out of 10). The pooled data from all the included studies indicated that the FIFA 11 and FIFA 11+ programs were effective in reducing the ankle injury rate by 14%, while pooled results from the studies that used the FIFA 11+ program significantly reduced ankle injury rate by 32%. However, the FIFA 11 program was not effective in reducing the ankle injury rate. Conclusion: The FIFA programs, and especially the FIFA 11+ program, appear to be more effective than the usual training in preventing ankle injuries among footballers.
Peripheral abdominal nerve blocks are key components of multimodal analgesia, enhancing recovery after cesarean sections. This systematic review and meta-analysis aimed to assess analgesic efficacy of Erector Spinae Plane Block (ESPB) versus Transversus Abdominis Plane Block (TAPB) under ultrasound guidance following Cesarean Section (CS) under spinal anesthesia. A comprehensive search was conducted across PubMed, Scopus, Cochrane Library, and ISI Web of Science to identify relevant trials. The inclusion criteria followed the PICOS framework: Population (women undergoing elective cesarean delivery), Intervention (ESPB), Comparator (TAPB), Outcomes (postoperative pain, opioid consumption, analgesic duration, and satisfaction), and Study Design (randomized controlled trials). Seven RCTs (380-patients) met the inclusion criteria. The ESPB group had significantly lower postoperative pain scores at rest and during movement, reduced 24-hour opioid consumption (MD = -2.62 MME; 95% CI -4.11 to -1.13; p = 0.006), and longer analgesic duration (SMD = 1.77; 95% CI 1.11 to 2.44; p < 0.001) than the TAPB group. Patient satisfaction was also significantly higher in the ESPB group (OR = 4.75; 95% CI 2.26 to 9.99; p < 0.001). While most outcomes demonstrated low heterogeneity, significant variability was observed in analgesic duration (I 2 = 83%), requiring cautious interpretation. The ESP block offers superior pain relief, reduces opioid use, and enhances satisfaction compared to the TAP block in cesarean sections. These findings suggest that the implementation of the ESP block in postoperative analgesia protocols could significantly improve patient outcomes, potentially leading to enhanced recovery and reduced reliance on opioids.
Congenital diaphragmatic hernia (CDH) is a rare but critical surgical disorder that can be managed using either open or thoracoscopic surgical approaches. However, the optimal approach remains a topic of debate. This study aimed to evaluate the efficacy and safety of thoracoscopic repair compared to open repair in patients with CDH. An extensive literature search was conducted across four databases (PubMed, Web of Science, Scopus, and Cochrane Library) from inception to May 2024, including all relevant studies comparing the two surgical modalities. Key outcomes assessed were hospital stay duration, operation time, mortality, and recurrence. Categorical outcomes were analyzed using the risk ratio (RR) with 95% confidence intervals (CI), while continuous outcomes were analyzed using the mean difference (MD) with 95% CI. Data analysis was performed using Review Manager (RevMan, Version 5.3). A total of 35 studies involving 1,680 individuals with CDH were included in our analysis. The pooled results revealed that thoracoscopic repair was associated with a shorter hospital stay (MD=-6.80, 95% CI [-9.39, -4.21], p< 0.0001) but a longer operation time (MD=23.30, 95% CI [7.22, 39.38], p=0.005) compared to the open approach. Additionally, thoracoscopic repair demonstrated lower mortality rates (RR=0.43, 95% CI [0.24, 0.76], p=0.004) but higher recurrence rates (RR=2.24, 95% CI [1.56, 3.21], p<0.0001) than open repair. Our findings suggest that thoracoscopic repair offers shorter hospital stays and lower mortality rates but involves longer operation times and higher recurrence rates compared to the open approach. These results highlight the need for further large, multicenter, randomized controlled trials to validate our findings and guide clinical decision-making.
congenital diaphragmatic herniathoracoscopic repairopen surgical repairminimally invasive surgery
BACKGROUND: Respiratory Distress Syndrome (RDS) remains a leading cause of mortality among preterm infants weighing < 2000 g, particularly in resource-limited settings. While Kangaroo Mother Care (KMC) has shown promise in stable preterm infants, its effectiveness for those requiring respiratory support remains unclear. This study evaluated nurse-led implementation of KMC for preterm infants with RDS. METHODS: A prospective, multicenter, randomized controlled trial was conducted across four neonatal intensive care units in Tanta, Egypt (January 2023-June 2024). Two hundred forty preterm infants (<2000 g) with RDS were randomly assigned to either nurse-implemented KMC (n = 120) or standard care (n = 120). The KMC protocol, implemented for a minimum of 6 h per day until hospital discharge, integrated continuous skin-to-skin contact, exclusive breastfeeding promotion, and structured parental education. Outcomes included 28-day survival, respiratory status (Silverman-Anderson Scores), nosocomial infections, maternal-infant bonding, growth trajectories, and clinical course metrics. RESULTS: The KMC intervention significantly improved 28-day survival (adjusted HR = 0.42, 95% CI 0.28-0.63, p < 0.001) and reduced nosocomial infections by 55% (RR = 0.45, 95% CI 0.27-0.75, p < 0.001). KMC recipients demonstrated faster respiratory improvement, shorter CPAP duration (-2.2 days, p < 0.001), and higher rates of exclusive breastfeeding at discharge (74.2% vs. 48.3%, p < 0.001). Maternal competency scores showed progressive improvement with enhanced bonding and responsiveness. CONCLUSION: Nurse-implemented KMC is a safe, effective intervention for preterm infants with RDS, yielding significant improvements in survival, clinical outcomes, and family-centered care metrics. IMPLICATIONS FOR PRACTICE: These findings support the expansion of nursing roles in implementing KMC for high-risk infants in resource-limited settings. TRIAL REGISTRATION: ClinicalTrials.gov (NCT06707376).
BMC Pregnancy and Childbirth · مجلد 25 (1) · 1066-1066
BACKGROUND: Early breastfeeding initiation is crucial for low-birth-weight (LBW) infants, yet in-person lactation support may be limited in resource-poor settings. Telemedicine holds promise but lacks robust comparative evidence with traditional care. OBJECTIVE: To evaluate whether nurse-led telemedicine is non-inferior to in-person support on routine early-initiation performance in LBW/NICU settings, and to describe breastfeeding processes within 24 h postpartum. METHODS: This parallel-group, non-inferiority randomized controlled trial included 200 mothers of LBW infants admitted to four neonatal intensive care units (NICUs) in Egypt. Participants were randomized (1:1) to receive nurse-led telemedicine or standard in-person lactation support. Primary Process Outcome: Direct Breastfeeding Initiation within 1 Hour, assessed against a 5% non-inferiority margin. Secondary outcomes of maternal self-efficacy, satisfaction, state anxiety, and infant growth parameters were measured at baseline, one week, and one month postpartum. Analyses followed both intention-to-treat and per-protocol approaches. RESULTS: Breastfeeding initiation occurred in 65% of mothers in the telemedicine group versus 70% in the in-person group, confirming non-inferiority (p = 0.04). Although in-person support provided a minor short-term advantage in maternal self-efficacy at one week (49.2 ± 6.5 vs. 47.5 ± 7.2, p = 0.03), scores converged by one month (p = 0.45). Telemedicine participants reported higher satisfaction with accessibility (p = 0.03), while overall support quality, anxiety reduction, and infant growth measures were comparable between groups. Parity and socioeconomic status independently predicted breastfeeding initiation (p < 0.01). CONCLUSIONS: Nurse-led telemedicine did not reduce first-hour initiation relative to in-person support; given stabilization protocols in LBW/NICU care, this endpoint functions as a process benchmark rather than a direct target of the support modality. Although in-person support may offer early advantages in maternal self-efficacy, telemedicine effectively sustains key outcomes over time and can expand equitable breastfeeding support in regions with limited healthcare resources. TRIAL REGISTRATION: ClinicalTrials.gov NCT06652386, Registered 22 October 2024.
breastfeeding initiationtelemedicinenurse-led carebreastfeeding support
Journal of Multidisciplinary Healthcare · مجلد Volume 18 · 1-12
Background: Background: Strain-Counterstrain (SCS) therapy is a manual therapeutic technique used to treat myofascial pain by addressing tender points through passive positioning. Despite anecdotal evidence, limited peer-reviewed research supports its efficacy in chronic low back pain (LBP). This study evaluates the effects of SCS combined with exercise on pain severity, lumbar range of motion (ROM), and functional disability in patients with chronic LBP. Methods: A randomized controlled trial was conducted with 30 participants aged 45-55 years, divided into Group A (SCS + Exercise) and Group B (Exercise Only). Outcome measures included pain intensity, lumbar ROM (flexion, extension, side bending), and functional disability (Oswestry Disability Index). Assessments were conducted at baseline and after four weeks of intervention. MANOVA was performed to evaluate group, time, and interaction effects, with detailed univariate follow-ups and effect sizes. Reliability of ROM measurements was ensured using intraclass correlation coefficients (ICC > 0.90). Results: MANOVA revealed statistically significant group, time, and interaction effects for all outcomes (Wilks' Lambda = 0.065, F (6, 51) = 91.34, p < 0.001). Pain severity decreased by 26.7% in Group A compared to 5.2% in Group B (F (1, 56) = 65.78, p < 0.001, partial η² = 0.77). Lumbar ROM improved significantly in Group A for flexion (10.9%), extension (20.3%), and right-side bending (17.7%) (p < 0.001, partial η² = 0.68-0.74), with no significant improvement in left-side bending. Functional disability scores reduced by 25.2% in Group A versus 2.3% in Group B (F (1, 56) = 53.45, p < 0.001, partial η² = 0.73). Conclusion: SCS therapy combined with exercise significantly reduces pain, improves lumbar ROM, and enhances functional capacity in patients with chronic LBP compared to exercise alone. These findings highlight SCS as a promising adjunctive treatment for managing chronic musculoskeletal pain. Future studies should investigate long-term outcomes and further refine treatment protocols.
chronic low back painmyofascial pain syndromeexercise therapylumbar range of motion
BACKGROUND: Dupilumab is a human monoclonal antibody targeting the IL-4 receptor. There is a paucity of evidence regarding its efficacy and safety in pediatrics. Pediatric-specific data are limited, and most evidence comes from recent phase 3 trials and post hoc analyses. OBJECTIVE: To summarize the current evidence of the efficacy, safety, and biomarker effects of dupilumab in children with moderate-to-severe asthma, while identifying key gaps in the pediatric evidence base. METHODS: This study is a systematic review following PRISMA guidelines, and aims to assess the efficacy, safety, and biomarker response of dupilumab in pediatric patients with moderate to severe asthma. We evaluated the studies using the Cochrane Risk of Bias Tool 2.0. RESULTS: Six studies from 2021 to 2024 met the inclusion criteria: three of them are phase 3 randomized controlled trials and the other three post hoc analyses, mostly including children aged 6-11 years with type 2 inflammation, defined by elevated blood eosinophils and/or FeNO. Both allergic and nonallergic asthma phenotypes were represented across studies, with post hoc analyses indicating consistent benefit in each group. Dupilumab decreased the rate of severe exacerbations annually by 59.3% in children with type 2 inflammation. The study populations are mainly children between 6 and 11 years of age with moderate-to-severe asthma, characterized by eosinophilic or allergic phenotypes (type 2 asthma), including those with elevated blood eosinophils and/or FeNO levels. Dupilumab reduced the annual rate of severe exacerbation by ~59%, with greater reductions in children with FeNO ≥50 ppb (69%) or eosinophils ≥300 cells/µL (65%). The lung function showed improvement by 0.15-0.30 L in pre-bronchodilator FEV₁, accompanied by gains in asthma control and quality of life. Biomarker reductions (FeNO, eosinophils, IgE, TARC) were consistent across phenotypes. Adverse event rates were like placebo; eosinophilia and injection site reactions were more common but usually mild. CONCLUSION: This systematic review provides an early synthesis of emerging pediatric phase 3 evidence on dupilumab. While results suggest substantial benefits in reducing exacerbations, improving lung function, and modulating type 2 biomarkers, the evidence remains limited to short-term studies in a narrow age range. Longer-term follow-up, broader age representation, and real-world data are needed to define the long-term role of dupilumab in pediatric asthma. Prospero Code: CRD42024557750.
Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity in individuals with type 2 diabetes mellitus (T2DM), contributing to increased liver-related complications and cardiovascular risk. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as potential treatments offering benefits for both metabolic and liver-related outcomes. This systematic review evaluated the efficacy of SGLT2 inhibitors in improving hepatic steatosis, liver enzymes, glycemic control, and liver histology in patients with T2DM and NAFLD. The review was conducted using a structured methodology, including systematic database searches and risk of bias assessments. Included randomized controlled trials (RCTs) investigated various SGLT2 inhibitors, such as dapagliflozin, empagliflozin, ertugliflozin, and ipragliflozin. Most studies showed significant reductions in liver fat content, improvements in serum liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT)), and favorable effects on blood pressure, triglycerides, and body composition. Glycemic control markers, including glycated hemoglobin (HbA1c), fasting glucose, and insulin resistance indices, also improved. One biopsy-based study demonstrated histological improvements, including reduced fibrosis and resolution of nonalcoholic steatohepatitis (NASH). No serious adverse events were reported. These findings suggest SGLT2 inhibitors may offer dual benefits for managing both diabetes and fatty liver disease. Further long-term studies focusing on liver histology as a primary endpoint are needed to confirm these effects.